Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer

Korean Journal of Internal Medicine

Volumn 20, Issue 3, 2005, Pages 205-209

  Lee, Myung Ah ^a   Byun, Jae Ho ^a,c   Shim, Byoung Young ^a   Woo, In Sook ^a   Kang, Jin Hyung ^a   Hong, Young Seon ^a   Lee, Kyung Shik ^a   Choi, Myung Gyu ^a   Chang, Suk Kyun ^a   Oh, Seong Taek ^a   Choi, Sung Il ^b   Lee, Doo Suk ^b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Daehang Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

5 FU; Colorectal cancer; Irinotecan; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 28444437108     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2005.20.3.205     Document Type: Article

References (17)

1. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 38:1000-1015, 2002
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047, 2000
4. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreatedmetastatic colorectal cancer. Eur J Cancer 35:1343-1347, 1999
5. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237, 2004
6. Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Hohler T, Galle PR, Heike M, Moehler M. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4:38, 2004
7. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Mery-Mignard D, Rougier P. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 17:2901-2908, 1999
8. Maroun JA, Cripps C, Goel R, Dahrouge S, Boisvert D. Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. Am J Clin Oncol 20:387-392, 1997
9. Kim JH, Kim DY, Lee SH, Park SR, Lee SY, Choi IS, Kim TY, Heo DS, Bang YJ, Kim NK. Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer. Korean J Med 64:452-458, 2003
10. Kwon HC, Kim SH, Kim JS, Kim HJ. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and low-Dose leucovorin every two weeks in patients with oxaliplatin pretreated metastatic colorectal cancer. Cancer Res Treat 35:135-140, 2003
11. Won YW, Lim YH, Park HY, Oh HS, Choi JH, Lee YY, Kim IS, Choi IY, Ahn MJ. Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy. Cancer Res Treat 36:235-239, 2004
12. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
13. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795, 1999
14. Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, Fiebiger W, Kovats E, Lang F, Depisch D. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 20:60-68, 2002
15. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13:1424-1429, 2002
16. Bouzid K, Khalfallah S, Tujakowski J, Piko B, Purkalne G, Plate S, Padrik P, Serafy M, Pshevloutsky EM, Boussard B. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and tolinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 14:1106-1114, 2003
17. Diasio R. Alternative schedules with irinotecan. Semin Oncol 30(4 Suppl 12):18-24, 2003